Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers

Organogenesis (ORGO) published peer-reviewed clinical trial results demonstrating that its Affinity product, when combined with standard wound care, significantly improved closure rates in complex venous leg ulcers at weeks 12 and 16. The trial was a prospective, multicenter, randomized controlled design—the gold standard for clinical evidence—making this a meaningful validation of therapeutic efficacy in a challenging patient population.

Venous leg ulcers represent a high-morbidity chronic wound segment with limited effective treatment options, particularly for complex cases resistant to conventional management. Publication in the Journal of Wound Care provides third-party credibility and positions ORGO's Affinity as a differentiated solution in the advanced wound care market, potentially expanding reimbursement pathways and clinical adoption among wound care specialists.

The statistically significant improvement across multiple wound duration strata strengthens the clinical evidence base and may support broader label expansion or off-label use scenarios. This type of peer-reviewed validation typically reduces clinical skepticism and can accelerate hospital formulary adoption, though regulatory pathway clarity and payer coverage decisions remain critical variables.

Sector implication: The regenerative medicine and advanced wound care segments are experiencing consolidation and innovation-driven pricing power. Clinical data releases like this support margin expansion for specialized wound care providers by justifying premium positioning relative to commoditized alternatives, favorable to mid-cap biotech/med-device players with targeted therapeutic niches.